Pages that link to "Q36194119"
Jump to navigation
Jump to search
The following pages link to Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review (Q36194119):
Displaying 50 items.
- Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells (Q24316354) (← links)
- Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid (Q24536167) (← links)
- Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice (Q24600864) (← links)
- Hypertriglyceridemia: its etiology, effects and treatment (Q24672914) (← links)
- Niacin, an old drug with a new twist (Q27002774) (← links)
- Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1 (Q28221789) (← links)
- Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? (Q28222549) (← links)
- Nicotinic acid receptor agonists differentially activate downstream effectors (Q28298974) (← links)
- Niacin stimulates adiponectin secretion through the GPR109A receptor (Q28575089) (← links)
- Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists (Q28583868) (← links)
- Study to explore the mechanism to form inclusion complexes of β-cyclodextrin with vitamin molecules (Q28821499) (← links)
- Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis (Q33410839) (← links)
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors (Q33590777) (← links)
- Oral β-hydroxybutyrate increases ketonemia, decreases visceral adipocyte volume and improves serum lipid profile in Wistar rats (Q33601233) (← links)
- Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats (Q33646129) (← links)
- Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathway (Q33758775) (← links)
- A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. (Q33765072) (← links)
- Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. (Q33802196) (← links)
- Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile (Q33863355) (← links)
- Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia (Q33935328) (← links)
- Experimental IR and Raman spectra and quantum chemical studies of molecular structures, conformers and vibrational characteristics of nicotinic acid and its N-oxide (Q33942863) (← links)
- Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3. (Q33991193) (← links)
- Seeing red: flushing out instigators of niacin-associated skin toxicity. (Q34028776) (← links)
- How much do we really know about our favorite cosmeceutical ingredients? (Q34066235) (← links)
- American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary (Q34081331) (← links)
- Future of GPR109A agonists in the treatment of dyslipidaemia (Q34171831) (← links)
- Obesity, cholesterol metabolism, and breast cancer pathogenesis (Q34204836) (← links)
- Extended-release niacin acutely suppresses postprandial triglyceridemia (Q34223452) (← links)
- Niacin: another look at an underutilized lipid-lowering medication (Q34255686) (← links)
- Niacin: chemical forms, bioavailability, and health effects (Q34278034) (← links)
- Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease (Q34300722) (← links)
- Progress in genetic association studies of plasma lipids. (Q34465095) (← links)
- Nicotinic acid modulates intracellular calcium concentration and disassembles the cytoskeleton (Q34487985) (← links)
- Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages (Q34565228) (← links)
- The flavonoid luteolin inhibits niacin-induced flush (Q34587640) (← links)
- HDL and cognition in neurodegenerative disorders. (Q34614842) (← links)
- Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells (Q34624990) (← links)
- Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. (Q34805517) (← links)
- Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia (Q35026444) (← links)
- Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue (Q35055437) (← links)
- Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study (Q35072453) (← links)
- Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises (Q35190833) (← links)
- Molecular regulation of HDL metabolism and function: implications for novel therapies (Q35191066) (← links)
- Pharmacological doses of niacin stimulate the expression of genes involved in carnitine uptake and biosynthesis and improve the carnitine status of obese Zucker rats (Q35204914) (← links)
- Effects of Nicotinic Acid on Gene Expression: Potential Mechanisms and Implications for Wanted and Unwanted Effects of the Lipid-Lowering Drug (Q35432791) (← links)
- Niacin reverses migratory macrophage foam cell arrest mediated by oxLDL in vitro (Q35529487) (← links)
- Retinal transfer of nicotinate by H -monocarboxylate transporter at the inner blood-retinal barrier (Q35575652) (← links)
- Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis (Q35608570) (← links)
- The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis (Q35622086) (← links)
- Ocular Effects of Niacin: A Review of the Literature (Q35690848) (← links)